Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.ortinlabsindia.com | |
Market Cap | 20.90 Cr. | |
Enterprise Value(EV) | 28.06 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.06 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 24.36 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 14.04 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 1.83 | Calculated using Price: 25.70 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 0.81 Cr. | 8,131,392 Shares |
FaceValue | 10 | |
Company Profile | ||
Ortin Laboratories established in the year 1986 was a private limited company with a nominal capital of Rs 1 lakh to offer quality drugs and medicines to the suffering mankind. Later, in the year 1994, this private limited company converted as a public limited company with 5,060 shareholders which received good subscription from the public. These proceeds were utilised for constructing a factory in a spacious area of 25000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of Tablets, Capsules, Syrups, Dry Powders & Ointments. Due to its concern for quality, the company stands as a leading and predominant pharmaceutical manufacturer of drugs and medicines of the country with turnover running in crores of rupees. Quality is the hallmark of Ortin. At every stage of production from raw material to finished products, highest standard of quality is ensured with the help of most modern equipment and experienced personnel.This unflinching perseverance towards quality has helped the company to earn enormous goodwill & trust, both from medical profession and pharmaceutical trade. Being in partnership with the world means respecting its resources without compromise and so at Ortin, continuous process evaluation and monitoring waste recoveries ensure that the focus is maintained. Specialized facilities have helped us to earn a reputation for the expert handling of hazardous materials in the form of reactants and products. Teams from the ministry of health regularly inspect the company's plant. Every care is taken for treatment of solid wasters, discharged liquids and atmospheric releases. Ortin is contemplating an entry into the OTC segment as part of its long term growth strategy. It is channeling its efforts towards building an overseas marketing network in order to enhance exports to third world countries. Ortin proposes to be certified as a WHO GMP Unit and to launch innovative Biotechnology products in Orthopedic and Dental Segments. The success behind them is only the Reliance which they carry for their Quality from the people all over the country. Their motto, right from their inception has been towards Quality and they still maintain them and continue to do so in future. Products manufactured by the company include:
Achievements/ recognition :
|
1 Day |
|
|
1 Week |
|
+11.59% |
1 Month |
|
-6.31% |
3 Month |
|
-6.64% |
6 Month |
|
-8.29% |
1 Year |
|
-13.33% |
2 Year |
|
+127.07% |
5 Year |
|
+36.84% |
10 Year |
|
-6.47% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 5.34 | 5.55 | 4.04 | 3.65 | 2.16 | 2.86 | 5.21 | -2.31 | 5.38 | |
Return on Capital Employed (%) | 15.05 | 13.62 | 11.55 | 11.01 | 9.58 | 10.14 | 11.76 | 8.93 | 3.27 | |
Return on Assets (%) | 1.40 | 1.62 | 1.28 | 1.25 | 0.79 | 1.00 | 1.43 | -0.51 | 1.37 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 21 | 22 | 22 | 23 | 23 | 24 | 25 | 24 | 11 | 12 | |
Non Curr. Liab. | 4 | 6 | 8 | 16 | 8 | 8 | 8 | 9 | 2 | 2 | |
Curr. Liab. | 49 | 45 | 37 | 27 | 31 | 42 | 72 | 84 | 8 | 8 | |
Minority Int. | |||||||||||
Equity & Liab. | 73 | 73 | 68 | 66 | 62 | 74 | 105 | 117 | 21 | 22 | |
Non Curr. Assets | 27 | 26 | 24 | 35 | 23 | 21 | 23 | 24 | 15 | 15 | |
Curr. Assets | 46 | 47 | 44 | 31 | 38 | 52 | 82 | 92 | 6 | 7 | |
Misc. Exp. not W/O | 0 | ||||||||||
Total Assets | 73 | 73 | 68 | 66 | 62 | 74 | 105 | 117 | 21 | 22 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 75 | 67 | 60 | 63 | 67 | 80 | 168 | 197 | 8 | 8 | |
Other Income | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |
Total Income | 75 | 68 | 61 | 64 | 67 | 80 | 168 | 198 | 8 | 8 | |
Total Expenditure | -68 | -61 | -54 | -57 | -61 | -74 | -162 | -192 | -7 | -7 | |
PBIDT | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 1 | 1 | |
Interest | -4 | -4 | -4 | -3 | -3 | -3 | -3 | -3 | -1 | -1 | |
Depreciation | -1 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | 0 | 0 | |
Taxation | -1 | -1 | 0 | -1 | -1 | -1 | -1 | 1 | 1 | ||
Exceptional Items | |||||||||||
PAT | 1 | 1 | 1 | 1 | 1 | 1 | 1 | -1 | 1 | 1 | |
Adjusted EPS | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | -2 | -2 | -1 | 1 | 2 | 2 | 7 | 3 | 18 | |
Cash Fr. Inv. | -2 | -2 | 0 | 0 | -1 | -1 | -1 | -3 | -3 | 0 | |
Cash Fr. Finan. | 2 | 5 | 1 | 2 | 0 | -1 | 0 | -3 | -1 | -10 | |
Net Change | 0 | 1 | -1 | 1 | 0 | 0 | 1 | 0 | -1 | 8 | |
Cash & Cash Eqvt | 1 | 2 | 1 | 2 | 2 | -14 | -13 | -13 | -14 | -5 |
Mon, 16 May 2022
Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended 31.03.2022 Ortin Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve audited financial results for the quarter and year ended 31.03.2022 |
||||||||||||||
Thu, 14 Apr 2022
Statement Of Investor Complaints For The Quarter Ended March 2022
|
||||||||||||||
Wed, 13 Apr 2022
Compliances Certificate Under Reg. 7(3) Compliances certificate under reg. 7(3) |
Wed, 18 May 2022 |
|
|
|
|
|